Reader Mailbag – TCR T cell Gene Editing in Multiple Myeloma
I was thinking that the reader mailbag questions this week would be full of straightforward easy to answer clinical questions, after all, they usually are post ASH and ASCO… but not this year!
T-cells attacking a cancer cell. Digital illustration.
Instead, there is a huge wall of intense focus on CAR T cell therapies and the latest round of intriguing developments in this space. While CARs have received much attention, TCR cell products have largely flown under the radar to date, although that may change.
What’s particularly interesting is that these charges could potentially be transformative or absolute duds – it’s unlikely to be an indifferent middle ground here.
Here, we answer questions on the ever-increasingly complex science that is ongoing in the TCR and CAR T cell fields.
In the next mailbag, we will cover the clinical questions arising from data at ASCO, so if you have any queries on the data in Chicago, there’s still time to send them in before next Friday!
If you are interested in the new developments in the complex world of gene editing and how they may impact the ever-changing adoptive cell therapy space, then this article is for you. Subscribers can log-in below or you can click the Blue Box to nab instant access!
This content is restricted to subscribers
